UstekiRel
Ustekinumab biosimilar developed by Reliance Life Sciences. Reference product Stelara.
About UstekiRel
UstekiRel is Reliance Life Sciences' ustekinumab, permitted in India in April 2023 for plaque psoriasis, with psoriatic arthritis added in December 2024. It is the only ustekinumab biosimilar made in India, and one of the few Indian permissions where the published record names the brand.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India · UstekiRel
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Same developer, other molecules
Other biosimilars in the Atlas developed by Reliance Life Sciences: Reliance Life Sciences adalimumab, Reliance Life Sciences bevacizumab, Reliance Life Sciences darbepoetin alfa, Reliance Life Sciences denosumab, Reliance Life Sciences etanercept, Reliance Life Sciences follitropin alfa, Reliance Life Sciences golimumab, Reliance Life Sciences infliximab, Reliance Life Sciences omalizumab, Reliance Life Sciences ranibizumab, Reliance Life Sciences rituximab, Reliance Life Sciences somatropin, Reliance Life Sciences trastuzumab.
Chronology
- CDSCOApr 2023CDSCO permission granted
Sources
Planning ustekinumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant